HCW Biologics Net Income
| HCWB Stock | USD 1.03 0.08 7.21% |
As of the 5th of February, HCW Biologics retains the coefficient of variation of (453.21), and Market Risk Adjusted Performance of 1.3. HCW Biologics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the entity's future prices.
HCW Biologics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 22.1577 | Revenue | Earnings Share (16.41) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -27 M | -25.7 M | |
| Net Loss | -13.4 M | -14.1 M | |
| Net Loss | -27 M | -25.7 M | |
| Net Loss | (0.89) | (0.93) | |
| Net Income Per E B T | 0.90 | 0.80 |
HCW | Net Income | Build AI portfolio with HCW Stock |
Analyzing HCW Biologics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing HCW Biologics's current valuation and future prospects.
Latest HCW Biologics' Net Income Growth Pattern
Below is the plot of the Net Income of HCW Biologics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in HCW Biologics financial statement analysis. It represents the amount of money remaining after all of HCW Biologics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is HCW Biologics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HCW Biologics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (30.02 M) | 10 Years Trend |
|
Net Income |
| Timeline |
HCW Net Income Regression Statistics
| Arithmetic Mean | (12,598,950) | |
| Coefficient Of Variation | (67.86) | |
| Mean Deviation | 7,044,630 | |
| Median | (7,292,921) | |
| Standard Deviation | 8,549,658 | |
| Sample Variance | 73.1T | |
| Range | 24.2M | |
| R-Value | (0.80) | |
| Mean Square Error | 27.8T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | (1,358,149) | |
| Total Sum of Squares | 1169.5T |
HCW Net Income History
Other Fundumenentals of HCW Biologics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
HCW Biologics Net Income component correlations
HCW Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for HCW Biologics is extremely important. It helps to project a fair market value of HCW Stock properly, considering its historical fundamentals such as Net Income. Since HCW Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of HCW Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of HCW Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. Market participants price HCW higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive HCW Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (16.41) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
Investors evaluate HCW Biologics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating HCW Biologics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause HCW Biologics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, HCW Biologics' market price signifies the transaction level at which participants voluntarily complete trades.
HCW Biologics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to HCW Biologics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of HCW Biologics.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in HCW Biologics on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding HCW Biologics or generate 0.0% return on investment in HCW Biologics over 90 days. HCW Biologics is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, OSR Holdings, Lipocine, and SeaStar Medical. HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunothe... More
HCW Biologics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure HCW Biologics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess HCW Biologics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.23) | |||
| Maximum Drawdown | 41.72 | |||
| Value At Risk | (11.97) | |||
| Potential Upside | 13.02 |
HCW Biologics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for HCW Biologics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as HCW Biologics' standard deviation. In reality, there are many statistical measures that can use HCW Biologics historical prices to predict the future HCW Biologics' volatility.| Risk Adjusted Performance | (0.15) | |||
| Jensen Alpha | (1.55) | |||
| Total Risk Alpha | (2.16) | |||
| Treynor Ratio | 1.29 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of HCW Biologics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
HCW Biologics February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | 1.3 | |||
| Mean Deviation | 4.99 | |||
| Coefficient Of Variation | (453.21) | |||
| Standard Deviation | 7.28 | |||
| Variance | 53.02 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (1.55) | |||
| Total Risk Alpha | (2.16) | |||
| Treynor Ratio | 1.29 | |||
| Maximum Drawdown | 41.72 | |||
| Value At Risk | (11.97) | |||
| Potential Upside | 13.02 | |||
| Skewness | 0.6508 | |||
| Kurtosis | 2.43 |
HCW Biologics Backtested Returns
HCW Biologics holds Efficiency (Sharpe) Ratio of -0.2, which attests that the company had a -0.2 % return per unit of volatility over the last 3 months. HCW Biologics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out HCW Biologics' market risk adjusted performance of 1.3, and Coefficient Of Variation of (453.21) to validate the risk estimate we provide. The firm retains a Market Volatility (i.e., Beta) of -1.25, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning HCW Biologics are expected to decrease by larger amounts. On the other hand, during market turmoil, HCW Biologics is expected to outperform it. At this point, HCW Biologics has a negative expected return of -1.47%. Please make sure to check out HCW Biologics' value at risk, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if HCW Biologics performance from the past will be repeated at future time.
Auto-correlation | 0.44 |
Average predictability
HCW Biologics has average predictability. Overlapping area represents the amount of predictability between HCW Biologics time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of HCW Biologics price movement. The serial correlation of 0.44 indicates that just about 44.0% of current HCW Biologics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.44 | |
| Spearman Rank Test | 0.36 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
HCW Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, HCW Biologics reported net income of (30.02 Million). This is 108.8% lower than that of the Biotechnology sector and 142.86% lower than that of the Health Care industry. The net income for all United States stocks is 105.26% higher than that of the company.
HCW Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HCW Biologics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HCW Biologics could also be used in its relative valuation, which is a method of valuing HCW Biologics by comparing valuation metrics of similar companies.HCW Biologics is currently under evaluation in net income category among its peers.
HCW Biologics Institutional Holders
Institutional Holdings refers to the ownership stake in HCW Biologics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of HCW Biologics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing HCW Biologics' value.| Shares | Bridgeway Capital Management, Llc | 2025-03-31 | 0.0 | Justinvest Llc | 2025-06-30 | 0.0 | Two Sigma Investments Llc | 2025-03-31 | 0.0 | Virtu Financial Llc | 2025-03-31 | 0.0 | Xtx Topco Ltd | 2025-03-31 | 0.0 | Ae Wealth Management Llc | 2025-06-30 | 0.0 | J.w. Cole Advisors, Inc. | 2025-06-30 | 0.0 | Hightower Advisors, Llc | 2025-03-31 | 0.0 | Cresset Asset Management, Llc | 2025-06-30 | 0.0 | Golden State Wealth Management, Llc | 2025-06-30 | 10 K | Ubs Group Ag | 2025-06-30 | 9.5 K |
HCW Fundamentals
| Return On Equity | -277.26 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (528.87) % | ||||
| Current Valuation | 9.52 M | ||||
| Shares Outstanding | 2.15 M | ||||
| Shares Owned By Insiders | 27.30 % | ||||
| Shares Owned By Institutions | 2.24 % | ||||
| Number Of Shares Shorted | 21.44 K | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 8.63 X | ||||
| Revenue | 2.57 M | ||||
| Gross Profit | 166.57 K | ||||
| EBITDA | (27.68 M) | ||||
| Net Income | (30.02 M) | ||||
| Cash And Equivalents | 32.41 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 13.69 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 30.25 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (14.23 M) | ||||
| Short Ratio | 0.54 X | ||||
| Earnings Per Share | (16.41) X | ||||
| Target Price | 35.0 | ||||
| Number Of Employees | 36 | ||||
| Beta | 0.64 | ||||
| Market Capitalization | 5.36 M | ||||
| Total Asset | 30.24 M | ||||
| Retained Earnings | (100.56 M) | ||||
| Working Capital | (23.93 M) | ||||
| Net Asset | 30.24 M |
About HCW Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HCW Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HCW Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HCW Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:Check out For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. Market participants price HCW higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive HCW Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (16.41) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
Investors evaluate HCW Biologics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating HCW Biologics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause HCW Biologics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, HCW Biologics' market price signifies the transaction level at which participants voluntarily complete trades.